46 At 1-year follow-up, the patient was pain-free and returned to a satisfactory functional level
This study showed that the risk of recurrent pancreatitis in a cohort of patients taking GLP-1 receptor agonists (10%) was likely no greater than what is observed in the general population and that more than half of the episodes of recurrent pancreatitis were attributable to causes other than GLP-1 receptor agonist therapy

Major Ingredients Purified Water, Ethylhexyl Palmitate, Glycereth-26, Glycerin, Cetearyl Alcohol, Niacinamide, Hydrogenated Poly(C6-14 Olefin), Beeswax, Caprylic/Capric Triglyceride, Polyglyceryl-2 Stearate, Dipropylene Glycol, Isododecane, Glyceryl Stearate, Hydroxyethyl Acrylate/Sodium Acryloyldimethyl Taurate Copolymer, Stearyl Alcohol, Glycol Stearate SE, Sodium Polyacrylate, Hydroxyacetophenone, Stearic Acid, Dimethiconol, Dimethicone/Vinyl Dimethicone Crosspolymer, Hydrogenated Polydecene, Hydrogenated Lecithin, Tranexamic Acid (1,000ppm), Betaine, Glutathione (1,000ppm), Panthenol, Fragrance, Hippophae Rhamnoides Fruit Oil, Butylene Glycol, Adenosine, Sorbitan Isostearate, Caprylyl Glycol, Trideceth-6, 1,2-Hexanediol, Disodium EDTA, Sodium Hyaluronate, Ascorbic Acid Ingredients subject to change at manufacturer's discretion
Evaluation of oxidative stress in biological samples using the thiobarbituric acid reactive substances assay
Medhat Mikhael, MD, pain management specialist at MemorialCare Orange Coast Medical Center in Fountain Valley, California What did the study find